Vivos Therapeutics, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.2M | $5.1M | $3.8M | $6.8M | $3.8M | $3.0M | $3.7M | $3.9M |
| Cost of Revenue | $2.2M | $2.1M | $838.0K | $2.8M | $1.7M | $1.5M | $3.0M | $1.5M |
| Gross Profit | $3.0M | $3.1M | $3.0M | $3.9M | $2.1M | $1.5M | $2.1M | $2.3M |
| Gross Margin | 57.3% | 59.5% | 78.1% | 58.0% | 55.2% | 50.0% | 56.7% | 60.5% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $7.1M | $9.0M | $8.5M | $7.9M | $6.4M | $4.9M | $4.3M | $4.5M |
| Operating Income | $-4.8M | $-6.6M | $-6.4M | $-4.7M | $-4.9M | $-3.9M | $-2.8M | $-2.6M |
| Operating Margin | -93.6% | -128.7% | -166.8% | -69.8% | -127.4% | -129.9% | -75.9% | -68.5% |
| Interest Expense | $1.1M | $1.1M | — | $500.0K | — | — | — | — |
| Pretax Income | $-5.5M | $-7.8M | $-7.0M | $-5.4M | $-5.0M | $-3.9M | $-2.8M | $-2.6M |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-5.5M | $-7.7M | $-6.9M | $-5.4M | $-5.0M | $-3.9M | $-2.8M | $-2.6M |
| Net Margin | -106.4% | -149.4% | -180.3% | -79.6% | -131.2% | -128.1% | -76.4% | -67.8% |
| EPS (Basic) | $-0.31 | $-0.52 | $-0.58 | $-0.25 | $-0.28 | $-0.23 | $0.21 | $-0.05 |
| EPS (Diluted) | $-0.31 | $-0.52 | $-0.58 | $-0.25 | $-0.28 | $-0.23 | $0.21 | $-0.05 |
| Shares Outstanding (Basic) | 17.7M | 14.6M | 10.3M | 21.9M | 18.2M | 17.2M | 10.0M | 52.9M |
| Shares Outstanding (Diluted) | 17.7M | 14.6M | 10.3M | 21.9M | 18.2M | 17.2M | 10.0M | 52.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |